Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2020

01-12-2020 | Breast Cancer | ASO Author Reflections

ASO Author Reflections: Omission of Axillary Lymph Node Dissection for Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy: Not Ready for Primetime?

Authors: Muayad F. Almahariq, MD, PhD, Peter Y. Chen, MD, Nayana Dekhne, MD, Joshua T. Dilworth, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2020

Login to get access

Excerpt

Axillary lymph node dissection (ALND) serves to stage the axilla and provide regional control in breast cancer patients but adversely impacts quality of life.1 There have been increasing efforts over the last 2 decades to omit ALND in favor of the less morbid sentinel lymph node dissection (SLND). Two seminal trials, ACOSOG Z0011 and AMAROS, clearly established the feasibility of SLND alone in patients with limited nodal metastasis who do not receive neoadjuvant chemotherapy (NAC).2,3 However, it is unclear whether omission of ALND compromises clinical outcomes in patients with residual nodal disease following NAC. This question is the subject of the ongoing ALLIANCE A011202 trial. …
Literature
1.
Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.CrossRef
2.
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.CrossRef
3.
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 2011;305(6):569–75.CrossRef
4.
Metadata
Title
ASO Author Reflections: Omission of Axillary Lymph Node Dissection for Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy: Not Ready for Primetime?
Authors
Muayad F. Almahariq, MD, PhD
Peter Y. Chen, MD
Nayana Dekhne, MD
Joshua T. Dilworth, MD, PhD
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08966-w

Other articles of this Special Issue 3/2020

Annals of Surgical Oncology 3/2020 Go to the issue

ASO Author Reflections

ASO Author Reflections: Revisiting the Prognostic Significance of Grade in Papillary Thyroid Carcinoma

ASO Author Reflections

ASO Author Reflections: Conversion During Attempted Minimally Invasive Adrenalectomy for Adrenocortical Carcinoma: A Cautionary Tale

ASO Author Reflections

ASO Author Reflections: Use of Peritoneal Cancer Index (PCI) to Evaluate Carcinomatosis in Ovarian Cancer

Head and Neck Oncology

Neck Dissection for Adenoid Cystic Carcinoma

ASO Author Reflections

ASO Author Reflections: Relationship of Cancer Diagnosis to Complications Following Pancreatoduodenectomy for Duodenal Adenoma: Extreme Force Versus the Right Weapon for the Right Problem

Hepatobiliary Tumors

Chemoradiation for Patients with Resected Biliary Tract Cancers in the Adjuvant Setting: Reply to a Letter to the Editor